Publikationen

Publikationen (eine Auswahl):

  • Cardiac and cerebral manifestations of antiphospholipid syndrome Jung F, Miesbach W, Scharrer I. Z Kardiol. 2002 Aug;91(8):650-8.
  • Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin Miesbach W, Voigt J, Peetz D, Scharrer I. Med Klin (Munich).
    2003 Jun 15;98(6):339-43.
  • Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Koschmieder S, Miesbach W, Fauth F, Bojunga J, Scharrer I, Brodt HR. Blood Coagul Fibrinolysis. 2003 Jun;14(4):395-9.
  • W. Miesbach, J. Voigt, D. Peetz, I. Scharrer. Massive Blutungsneigung bei zwei Patienten mit Faktor V Hemmkörper und Antiphospholipid Antikörper nach Ciprofloxacin. Med Klin. 2003;15;98(6):339-43.
  • S. Koschmieder, W.Miesbach, F. Fauth, J. Bojunga, I. Scharrer, HR. Brodt. Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coagul Fibrinolysis. 2003;14:395-9
  • Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation. Miesbach W, Scharrer I, Asherson RA. Clin Rheumatol. 2004 Jun;23(3):256-61.
  • The antiphospholipid syndrome Miesbach W, Scharrer I. Dtsch Med Wochenschr. 2004 Nov 19;129(47):2547-52.
  • Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin. Miesbach W, Scharrer I. Thromb Haemost. 2005 May;93(5):1001-3
  • The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Böhm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H, Scharrer I. Br J Haematol. 2005 Jun;129(5):644-52.
  • Identification of thrombin antibodies in patients with antiphospholipid syndrome. Miesbach W, Matthias T, Scharrer I. Ann N Y Acad Sci. 2005 Jun;1050:250-6.
  • Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome. Miesbach W, Chapman J, Scharrer I. J Neurol Sci. 2005 Nov 15;238(1-2):93-5.
  • Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome. Miesbach W, Gökpinar B, Gilzinger A, Claus D, Scharrer I. Immunobiology. 2005;210(10):755-60.
  • Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Miesbach W, Gilzinger A, Gökpinar B, Claus D, Scharrer I. Clin Neurol Neurosurg. 2006 Feb;108(2):135-42.
  • Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Miesbach W, Scharrer I, Asherson R. Clin Rheumatol. 2006 Nov;25(6):840-4.
  • W. Miesbach, I. Scharrer, RA. Asherson. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clinical Rheumatology. 2006; Jan 25 [Epub ahead of print].
  • Fischer C, Buschmann K, Blank M, Stachl A, Miesbach W, Shoenfeld Y, Lackner KJ, von Landenberg P. Immunobiology. 2006;211(9):695-9. Epub 2006 Sep 7. Erratum in: Immunobiology. 2006;211(10):821.
  • The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S, Espinoza G, Font J; Members of CAPS Registry Group. Autoimmun Rev. 2006 Dec;6(2):94-7. Epub 2006 Jul 21.
  • High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin's lymphoma. Miesbach W, Scharrer I, Asherson RA. Clin Rheumatol. 2007 Jan;26(1):95-7.
  • The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Espinosa G, Bucciarelli S; Members of the CAPS Registry Group. Clin Rheumatol. 2007 Dec;26(12):2109-14.
  • Recurrent deep vein thrombosis, ovarian carcinoma and antibodies to mitochondria M5 in a patient with asymptomatic primary "plus" antiphospholipid syndrome: an unusual combination. Asherson RA, Schamroth-Rapaport N, Skudowitz B, Singh S, Marx D, Miesbach W. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):890-5.
  • Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Miesbach W. Semin Thromb Hemost. 2008 Apr;34(3):282-5.
  • Neurologic symptoms as a feature of the antiphospholipid syndrome. Miesbach W. Semin Thromb Hemost. 2008 Apr;34(3):286-9.
  • Laboratory Diagnosis and Clinical Manifestations of Patients with Dysfibrinogenemia Miesbach W. J Lab Med 2008;32:401-5.
  • Malignancies and Catastrophic Anti-phospholipid Syndrome. Miesbach W. Clin Rev Allergy Immunol. 2008 Dec 2.
  • Incidence, clinical characteristics, and long-term prognosis of travel-associated pulmonary embolism. Lehmann R, Suess C, Leus M, Luxembourg B, Miesbach W, Lindhoff-Last E, Zeiher AM, Spyridopoulos I. Eur Heart J. 2009 Jan;30(2):233-41. Epub 2008 Nov 21.